PAP Termination in OSA Associated With Risk for Adverse CV Events

Summary

The article discusses a study on the impact of discontinuing positive airway pressure (PAP) treatment for obstructive sleep apnea (OSA), which correlates to increased cardiovascular risks. The 'biotech' concept ties to the study's disclosure of affiliations with biotech and pharma companies, relevant to the listed tags involving intensive care and related medical conditions.